The ongoing COVID-19 pandemic caused by severe acute respiratory syndrome coronavirus 2 is a global public health crisis. Multiple observations indicate poorer post-infection outcomes for patients with cancer than for the general population. Herein, we highlight the challenges in caring for patients with acute leukaemias and myeloid neoplasms amid the COVID-19 pandemic. We summarise key changes related to service allocation, clinical and supportive care, clinical trial participation, and ethical considerations regarding the use of lifesaving measures for these patients. We recognise that these recommendations might be more applicable to high-income countries and might not be generalisable because of regional differences in health-care infrastructure, individual circumstances, and a complex and highly fluid health-care environment. Despite these limitations, we aim to provide a general framework for the care of patients with acute leukaemias and myeloid neoplasms during the COVID-19 pandemic on the basis of recommendations from international experts.

Special considerations in the management of adult patients with acute leukaemias and myeloid neoplasms in the COVID-19 era: recommendations from a panel of international experts / Zeidan A.M.; Boddu P.C.; Patnaik M.M.; Bewersdorf J.P.; Stahl M.; Rampal R.K.; Shallis R.; Steensma D.P.; Savona M.R.; Sekeres M.A.; Roboz G.J.; DeAngelo D.J.; Schuh A.C.; Padron E.; Zeidner J.F.; Walter R.B.; Onida F.; Fathi A.; DeZern A.; Hobbs G.; Stein E.M.; Vyas P.; Wei A.H.; Bowen D.T.; Montesinos P.; Griffiths E.A.; Verma A.K.; Keyzner A.; Bar-Natan M.; Navada S.C.; Kremyanskaya M.; Goldberg A.D.; Al-Kali A.; Heaney M.L.; Nazha A.; Salman H.; Luger S.; Pratz K.W.; Konig H.; Komrokji R.; Deininger M.; Cirici B.X.; Bhatt V.R.; Silverman L.R.; Erba H.P.; Fenaux P.; Platzbecker U.; Santini V.; Wang E.S.; Tallman M.S.; Stone R.M.; Mascarenhas J.. - In: THE LANCET. HAEMATOLOGY. - ISSN 2352-3026. - ELETTRONICO. - 7:(2020), pp. e601-e612. [10.1016/S2352-3026(20)30205-2]

Special considerations in the management of adult patients with acute leukaemias and myeloid neoplasms in the COVID-19 era: recommendations from a panel of international experts

Santini V.;
2020

Abstract

The ongoing COVID-19 pandemic caused by severe acute respiratory syndrome coronavirus 2 is a global public health crisis. Multiple observations indicate poorer post-infection outcomes for patients with cancer than for the general population. Herein, we highlight the challenges in caring for patients with acute leukaemias and myeloid neoplasms amid the COVID-19 pandemic. We summarise key changes related to service allocation, clinical and supportive care, clinical trial participation, and ethical considerations regarding the use of lifesaving measures for these patients. We recognise that these recommendations might be more applicable to high-income countries and might not be generalisable because of regional differences in health-care infrastructure, individual circumstances, and a complex and highly fluid health-care environment. Despite these limitations, we aim to provide a general framework for the care of patients with acute leukaemias and myeloid neoplasms during the COVID-19 pandemic on the basis of recommendations from international experts.
2020
7
e601
e612
Goal 3: Good health and well-being for people
Zeidan A.M.; Boddu P.C.; Patnaik M.M.; Bewersdorf J.P.; Stahl M.; Rampal R.K.; Shallis R.; Steensma D.P.; Savona M.R.; Sekeres M.A.; Roboz G.J.; DeAng...espandi
File in questo prodotto:
File Dimensione Formato  
COVId19 management.pdf

accesso aperto

Descrizione: pdf articolo in toto
Tipologia: Pdf editoriale (Version of record)
Licenza: Open Access
Dimensione 198.7 kB
Formato Adobe PDF
198.7 kB Adobe PDF

I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificatore per citare o creare un link a questa risorsa: https://hdl.handle.net/2158/1208093
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 55
  • ???jsp.display-item.citation.isi??? 49
social impact